Market Highlights: Nektar Therapeutics (NKTR) Ends on a High Note at 1.28

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of Nektar Therapeutics (NASDAQ: NKTR) closed at $1.28 in the last session, up 0.79% from day before closing price of $1.27. In other words, the price has increased by $0.79 from its previous closing price. On the day, 0.56 million shares were traded. NKTR stock price reached its highest trading level at $1.31 during the session, while it also had its lowest trading level at $1.24.

Ratios:

We take a closer look at NKTR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 5.15. In the meantime, Its Debt-to-Equity ratio is 2.76 whereas as Long-Term Debt/Eq ratio is at 2.49.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $2.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 19 ’24 when Zalevsky Jonathan sold 6,866 shares for $1.28 per share. The transaction valued at 8,788 led to the insider holds 250,804 shares of the business.

Wilson Mark Andrew sold 5,651 shares of NKTR for $7,233 on Aug 19 ’24. The Chief Legal Officer now owns 225,263 shares after completing the transaction at $1.28 per share. On Aug 19 ’24, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 14,881 shares for $1.28 each. As a result, the insider received 19,048 and left with 848,358 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 235621120 and an Enterprise Value of 183992736. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.53 while its Price-to-Book (P/B) ratio in mrq is 2.96. Its current Enterprise Value per Revenue stands at 1.975 whereas that against EBITDA is -1.43.

Stock Price History:

Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 0.80%, while the 200-Day Moving Average is calculated to be 26.11%.

Shares Statistics:

According to the various share statistics, NKTR traded on average about 1.70M shares per day over the past 3-months and 831500 shares per day over the past 10 days. A total of 191.38M shares are outstanding, with a floating share count of 177.81M. Insiders hold about 3.41% of the company’s shares, while institutions hold 71.61% stake in the company. Shares short for NKTR as of 1723680000 were 8473759 with a Short Ratio of 4.99, compared to 1721001600 on 9724532. Therefore, it implies a Short% of Shares Outstanding of 8473759 and a Short% of Float of 5.89.

Most Popular